Sclerostin and the regulation of bone formation: Effects in hip osteoarthritis and femoral neck fracture

Journal of Bone and Mineral Research

Volumn 25, Issue 8, 2010, Pages 1867-1876

  Power, Jon ^a   Poole, Kenneth E S ^a   Van Bezooijen, Rutger ^b   Doube, Michael ^c   Caballero Alías, Ana M ^a   Lowik, Clemens ^b   Papapoulos, Socrates ^b   Reeve, Jonathan ^a   Loveridge, Nigel ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Bone remodeling; Osteoarthritis; Osteocyte; Osteoporosis; Sclerostin

Indexed keywords

ALKALINE PHOSPHATASE; SCLEROSTIN;

ADULT; AGED; ARTICLE; BONE BIOPSY; BONE REMODELING; CONTROLLED STUDY; CORTICAL BONE; FEMALE; FEMUR NECK FRACTURE; FRACTURE FIXATION; HIP OSTEOARTHRITIS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OSSIFICATION; OSTEOBLAST; OSTEOCYTE; PROTEIN EXPRESSION;

AGED; ALKALINE PHOSPHATASE; BETA CATENIN; BONE MORPHOGENETIC PROTEINS; FEMALE; FEMORAL NECK FRACTURES; GENETIC MARKERS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; OSTEOARTHRITIS, HIP; OSTEOCYTES; OSTEOGENESIS;

EID: 77955174372     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbmr.70     Document Type: Article

References (58)

1. Mansell JP, Collins C, Bailey AJ. Bone, not cartilage, should be the major focus in osteoarthritis. Nat Clin Pract Rheumatol. 2007;3:306-307. (Pubitemid 46864879)
2. Poole KE, Compston JE. Osteoporosis and its management. BMJ. 2006;333:1251-1256.
3. Jordan GR, Loveridge N, Bell KL, et al. Increased femoral neck cancellous bone and connectivity in coxarthrosis (hip osteoarthritis). Bone. 2003;32:86-95.
4. Fazzalari NL, Parkinson IH. Femoral trabecular bone of osteoarthritic and normal subjects in an age and sex matched group. Osteoarthritis Cartilage. 1998;6:377-382.
5. Li B, Aspden RM. Composition and mechanical properties of cancellous bone from the femoral head of patients with osteoporosis or osteoarthritis. J Bone Miner Res. 1997;12:641-651. (Pubitemid 27155224)
6. Bell KL, Loveridge N, Jordan GR, Power J, Constant CR, Reeve J. A novel mechanism for induction of increased cortical porosity in cases of intracapsular hip fracture. Bone. 2000;27:297-304.
7. Power J, Loveridge N, Lyon A, Rushton N, Parker M, Reeve J. Bone remodeling at the endocortical surface of the human femoral neck: a mechanism for regional cortical thinning in cases of hip fracture. J Bone Miner Res. 2003;18:1775-1780.
8. Loughlin J, Dowling B, Chapman K, et al. Functional variants within the secreted frizzled-related protein 3 gene are associated with hip osteoarthritis in females. Proc Natl Acad Sci U S A. 2004;101:9757-9762.
9. Min JL, Meulenbelt I, Riyazi N, et al. Association of the Frizzled-related protein gene with symptomatic osteoarthritis at multiple sites. Arthritis Rheum. 2005;52:1077-1080.
10. Diarra D, Stolina M, Polzer K, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med. 2007;13:156-163. (Pubitemid 46245765)
11. Hopwood B, Tsykin A, Findlay DM, Fazzalari NL. Microarray gene expression profiling of osteoarthritic bone suggests altered bone remodelling, WNT and transforming growth factor-beta/bone morphogenic protein signalling. Arthritis Res Ther. 2007;9:R100.
12. Van Bezooijen RL, Dijke PT, Papapoulos SE, Lowik CWGM. SOST/ sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev. 2005;16:319-327.
13. Poole KES, Bezooijen RL, Loveridge N, et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J. 2005;19:1842-1844.
14. Ellies DL, Viviano B, McCarthy J, et al. Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity. J Bone Miner Res. 2006;21:1738-1749.
15. van Bezooijen RL, Svensson JP, Eefting D, et al. Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. J Bone Miner Res. 2007;22:19-28. (Pubitemid 46032593)
16. Li X, Zhang Y, Kang H, et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem. 2005;280:19883-19887.
17. Rawadi G, Vayssiere B, Dunn F, Baron R, Roman-Roman S. BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop. J Bone Miner Res. 2003;18:1842-1853.
18. Tang N, Song WX, Luo J, et al. BMP9-induced osteogenic differentiation of mesenchymal progenitors requires functional canonical Wnt/ beta-catenin signaling. J Cell Mol Med. 2009;138:2448-24464.
19. ten Dijke P, Krause C, de Gorter DJ, Lowik CW, van Bezooijen RL. Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling. J Bone Joint Surg Am. 2008;90 (Suppl 1):31-35.
20. Baron R, Rawadi G. Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology. 2007;148:2635-2643.
21. Balemans W, Ebeling M, Patel N, et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001;10:537-543.
22. Brunkow ME, Gardner JC, Van Ness J, et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet. 2001;68:577-589.
23. Balemans W, Patel N, Ebeling M, et al. Identification of a 52kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet. 2002;39:91-97.
24. Staehling-Hampton K, Proll S, Paeper BW, et al. A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. Am J Med Genet. 2002;110:144-152.
25. Li X, Ominsky MS, Niu QT, et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res. 2008;23:860-869.
26. van Bezooijen RL, Roelen BA, Visser A, et al. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med. 2004;199:805-814. (Pubitemid 38375200)
27. Winkler DG, Sutherland MK, Geoghegan JC, et al. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. Embo J. 2003;22:6267-6276.
28. Sutherland MK, Geoghegan JC, Yu C, Winkler DG, Latham JA. Unique regulation of SOST, the sclerosteosis gene, by BMPs and steroid hormones in human osteoblasts. Bone. 2004;35:448-454.
29. Sutherland MK, Geoghegan JC, Yu C, et al. Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation. Bone. 2004;35:828-835.
30. Robling AG, Niziolek PJ, Baldridge LA, et al. Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem. 2008;283:5866-5875.
31. Moustafa A, Sugiyama T, Saxon LK, et al. The mouse fibula as a suitable bone for the study of functional adaptation to mechanical loading. Bone. 2009;44:930-935.
32. Li X, Ominsky MS, Warmington KS, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res. 2009;24:578-588.
33. Padhi D, Stouch B, Jang G, et al. Anti-sclerostin antibody increases markers of bone formation in healthy postmenopausal women. J Bone Miner Res. 2007;22(Suppl1):S37.
34. Bell KL, Loveridge N, Power J, Rushton N, Reeve J. Intracapsular hip fracture: increased cortical remodeling in the thinned and porous anterior region of the femoral neck. Osteoporos Int. 1999; 10:248-257. (Pubitemid 29458721)
35. Bell KL, Loveridge N, Power J, Garrahan N, Meggitt BF, Reeve J. Regional differences in cortical porosity in the fractured femoral neck. Bone. 1999;24:57-64.
36. Jordan GR, Loveridge N, Power J, Clarke MT, Reeve J. Increased cancellous bone in the femoral neck of patients with coxarthrosis (hip osteoarthritis): a positive remodeling imbalance favoring bone formation. Osteoporos Int. 2003;14:160-165.
37. Parfitt AM. The physiological and clinical significance of bone histomorphometric data. In: Recker R, ed. Bone Histomorphometry. Techniques and Interpretation; 1983: pp 143-224.
38. Verborgt O, Gibson GJ, Schaffler MB. Loss of osteocyte integrity in association with microdamage and bone remodeling after fatigue in vivo. J Bone Miner Res. 2000;15:60-67. (Pubitemid 30026933)
39. Noble BS, Peet N, Stevens HY, et al. Mechanical loading: biphasic osteocyte survival and targeting of osteoclasts for bone destruction in rat cortical bone. Am J Physiol Cell Physiol. 2003;284:C934-943.
40. Pitsillides AA, Rawlinson SC, Suswillo RF, Bourrin S, Zaman G, Lanyon LE. Mechanical strain-induced NO production by bone cells: a possible role in adaptive bone (re)modeling? Faseb J. 1995;9:1614-1622.
41. Klein-Nulend J, Semeins CM, Ajubi NE, Nijweide PJ, Burger EH. Pulsating fluid flow increases nitric oxide (NO) synthesis by osteocytes but not periosteal fibroblasts - correlation with prostaglandin upregulation. Biochem Biophys Res Commun. 1995;217:640-648.
42. Turner CH, Pavalko FM. Mechanotransduction and functional response of the skeleton to physical stress: the mechanisms and mechanics of bone adaptation. J Orthop Sci. 1998;3:346-355.
43. Martin RB. Toward a unifying theory of bone remodeling. Bone. 2000;26:1-6.
44. Tatsumi S, Ishii K, Amizuka N, et al. Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction. Cell Metab. 2007;5:464-475.
45. Gross TS, King KA, Rabaia NA, Pathare P, Srinivasan S. Upregulation of osteopontin by osteocytes deprived of mechanical loading or oxygen. J Bone Miner Res. 2005;20:250-256.
46. Bonewald LF, Johnson ML. Osteocytes, mechanosensing and Wnt signaling. Bone. 2008;42:606-615.
47. Imai S, Heino TJ, Hienola A, et al. Osteocyte-derived HB-GAM (pleiotrophin) is associated with bone formation and mechanical loading. Bone. 2009;44:785-794.
48. Ko JY, Wang FS, Wang CJ, Wong T, Chou WY, Tseng SL. Increased Dickkopf-1 expression accelerates bone cell apoptosis in femoral head osteonecrosis. Bone. 2009.
49. O'Brien CA, Plotkin LI, Galli C, et al. Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS One. 2008;3:e2942.
50. Keller H, Kneissel M. SOST is a target gene for PTH in bone. Bone. 2005;37:148-158. (Pubitemid 40962421)
51. Irie K, Ejiri S, Sakakura Y, Shibui T, Yajima T. Matrix mineralization as a trigger for osteocyte maturation. J Histochem Cytochem. 2008;56: 561-567. (Pubitemid 351702300)
52. Zhang K, Barragan-Adjemian C, Ye L, et al. E11/gp38 selective expression in osteocytes: regulation by mechanical strain and role in dendrite elongation. Mol Cell Biol. 2006;26:4539-4552.
53. Brounais B, David E, Chipoy C, et al. Long term oncostatin M treatment induces an osteocyte-like differentiation on osteosarcoma and calvaria cells. Bone. 2009;44:830-839.
54. Grynpas MD, Alpert B, Katz I, Lieberman I, Pritzker KP. Subchondral bone in osteoarthritis. Calcif Tissue Int. 1991;49:20-26.
55. Boyde A, Jones S, Aerssens J, Dequeker J. Mineral density quantitation of the human cortical iliac crest by backscattered electron image analysis: Variations with age, sex and degree of osteoarthritis. Bone. 1995;16:619-627.
56. Fazzalari NL, Moore RJ, Manthey BA, Vernon-Roberts B. Comparative study of iliac crest and subchondral femoral bone in osteoarthritic patients. Bone. 1992;13:331-335.
57. Dunstan CR, Evans RA, Hills E, Wong SY, Higgs RJ. Bone death in hip fracture in the elderly. Calcif Tissue Int. 1990;47:270-275. (Pubitemid 20357371)
58. Power J, Noble BS, Loveridge N, Bell KL, Rushton N, Reeve J. Osteocyte lacunar occupancy in the femoral neck cortex: an association with cortical remodeling in hip fracture cases and controls. Calcif Tissue Int. 2001;69:13-19. (Pubitemid 32702260)